Ultragenyx Pharmaceutical IncRARE
Price$15.03

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $717M+28.0% YoYTTM through 30 Jun 2026
Net Income -$586MTTM through 30 Jun 2026
Free Cash Flow -$489MTTM through 30 Jun 2026

Margins

Current
Gross Margin83.8%
EBITDA Margin-69.0%
Operating Margin-79.5%
Net Margin-81.7%

Returns

-37.5%ROA

Balance Sheet Health

Debt / Equity-16.44x
Current Ratio1.73x
Net Debt$463M
Cash & Equivalents$125M

Quality Metrics

Altman Z-Score-5.30
Piotroski F-Score2 / 9
FCF Margin-68.2%
Rule of 40-62.4
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $673M
Diluted EPS-$5.83TTM
'20'21'22'23'24'25
FY2025: $-5.83

Dividend

No dividend

Capital Allocation

Capex Intensity0.6%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.